These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 17065692

  • 1. Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients.
    Ballani P, Tran MT, Navar MD, Davidson MB.
    Diabetes Care; 2006 Nov; 29(11):2504-5. PubMed ID: 17065692
    [No Abstract] [Full Text] [Related]

  • 2. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus.
    Crasto W, Jarvis J, Hackett E, Nayyar V, McNally PG, Davies MJ, Lawrence IG.
    Postgrad Med J; 2009 Apr; 85(1002):219-22. PubMed ID: 19417173
    [Abstract] [Full Text] [Related]

  • 3. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA, Kane MP, Busch RS.
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [Abstract] [Full Text] [Related]

  • 4. [Low carbohydrate diet slowed down the progression of renal insufficiency in type 2 diabetes. A case--difficult to draw conclusions].
    Vesti-Nielsen J, Westerlund P, Bygren P.
    Lakartidningen; 2007 Oct; 105(30-31):2094-7. PubMed ID: 18751447
    [No Abstract] [Full Text] [Related]

  • 5. Failure of insulin treatment in obese patients with non-insulin-dependent diabetes mellitus.
    Fassberg J, Toffler WL, Fields SA, Loriaux LD.
    J Fam Pract; 1993 Jul; 37(1):76-81. PubMed ID: 8345343
    [Abstract] [Full Text] [Related]

  • 6. Insulin therapy in type 2 diabetes.
    Wyne KL, Mora PF.
    Endocr Res; 2007 Jul; 32(3):71-107. PubMed ID: 18092196
    [No Abstract] [Full Text] [Related]

  • 7. U-500 concentrated regular insulin: practical application in the outpatient setting.
    Taylor S.
    Nurse Pract; 2012 Sep 10; 37(9):47-52. PubMed ID: 22922723
    [Abstract] [Full Text] [Related]

  • 8. [Insulin treatment in type 2 diabetes].
    Birkeland KI.
    Tidsskr Nor Laegeforen; 2006 Mar 23; 126(7):919-20. PubMed ID: 16554885
    [No Abstract] [Full Text] [Related]

  • 9. [Serum level of retinol-binding protein 4 in obese patients with insulin resistance and in patients with type 2 diabetes treated with metformin].
    Tajtáková M, Semanová Z, Ivancová G, Petrovicová J, Donicová V, Zemberová E.
    Vnitr Lek; 2007 Sep 23; 53(9):960-3. PubMed ID: 18019665
    [Abstract] [Full Text] [Related]

  • 10. Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes.
    Caballero AE.
    J Diabetes Complications; 2009 Sep 23; 23(2):143-52. PubMed ID: 18413192
    [Abstract] [Full Text] [Related]

  • 11. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug 23; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 12. Impact of moderate aerobic exercise training on insulin sensitivity in type 2 diabetic men treated with oral hypoglycemic agents: is insulin sensitivity enhanced only in non-obese subjects?
    Bense L.
    Med Sci Monit; 2002 Jun 23; 8(6):LE23; discussion L24. PubMed ID: 12134782
    [No Abstract] [Full Text] [Related]

  • 13. [Blood pressure and type 2 diabetes mellitus: impact of the insulin therapy].
    Dakhli S, Lamine S, Lamine F, Trabelsi N, Aouididi F, Zouaoui C, Mami FB, Achour A.
    Tunis Med; 2007 Nov 23; 85(11):945-50. PubMed ID: 19166146
    [Abstract] [Full Text] [Related]

  • 14. Assessing the controversies of insulin therapy in patients with type 2 diabetes mellitus.
    Kuritzky L, Nelson SE.
    J Fam Pract; 2005 Jun 23; 54(6):S3-6. PubMed ID: 16021782
    [No Abstract] [Full Text] [Related]

  • 15. The role of basal insulin in type 2 diabetes management.
    Brunton SA, White JR, Renda SM.
    J Fam Pract; 2005 Oct 23; Suppl():S1-8. PubMed ID: 16271258
    [No Abstract] [Full Text] [Related]

  • 16. Re: Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
    Currie CJ, Evans M, Poole CD.
    Diabetes Obes Metab; 2008 Jan 23; 10(1):94-5. PubMed ID: 18095951
    [No Abstract] [Full Text] [Related]

  • 17. Dramatic improvement of subcutaneous insulin resistance with nafamostat ointment treatment.
    Kawashima S, Kaneto H, Sakamoto K, Honsho I, Yasuda T, Kuroda A, Shiraiwa T, Kasami R, Matsuoka TA, Yamasaki Y, Matsuhisa M.
    Diabetes Care; 2008 Mar 23; 31(3):e11. PubMed ID: 18308674
    [No Abstract] [Full Text] [Related]

  • 18. Switching from an oral regimen to insulin in diabetes.
    Perry M.
    Community Nurse; 2000 May 23; 6(4):27-8. PubMed ID: 12778520
    [No Abstract] [Full Text] [Related]

  • 19. [Performance of real-world studies for inhaled insulin].
    Göke B.
    Dtsch Med Wochenschr; 2005 Jul 08; 130 Suppl 2():S91-4. PubMed ID: 15988676
    [No Abstract] [Full Text] [Related]

  • 20. Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents.
    Yang WY, Ji QH, Zhu DL, Yang JK, Chen LL, Liu ZM, Yu DM, Yan L.
    Chin Med J (Engl); 2009 Jul 20; 122(14):1704-8. PubMed ID: 19719975
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.